Literature DB >> 24946104

PKC inhibition results in a Kv 1.5 + Kv β1.3 pharmacology closer to Kv 1.5 channels.

A Macías1, A de la Cruz, A Prieto, D A Peraza, M M Tamkun, T González, C Valenzuela.   

Abstract

BACKGROUND AND
PURPOSE: The Kv β1.3 subunit modifies the gating and pharmacology of Kv 1.5 channels in a PKC-dependent manner, decreasing channel sensitivity to bupivacaine- and quinidine-mediated blockade. Cardiac Kv 1.5 channels associate with receptor for activated C kinase 1 (RACK1), the Kv β1.3 subunit and different PKC isoforms, resulting in the formation of a functional channelosome. The aim of the present study was to investigate the effects of PKC inhibition on bupivacaine and quinidine block of Kv 1.5 + Kv β1.3 channels. EXPERIMENTAL APPROACH: HEK293 cells were transfected with Kv 1.5 + Kv β1.3 channels, and currents were recorded using the whole-cell configuration of the patch-clamp technique. PKC inhibition was achieved by incubating the cells with either calphostin C or bisindolylmaleimide II and the effects of bupivacaine and quinidine were analysed. KEY
RESULTS: The voltage-dependent inactivation of Kv 1.5 + Kv β1.3 channels and their pharmacological behaviour after PKC inhibition with calphostin C were similar to those displayed by Kv 1.5 channels alone. Indeed, the IC50 values for bupivacaine were similar in cells whose PKC was inhibited with calphostin C or bisindolylmaleimide II. Similar results were also observed in the presence of quinidine. CONCLUSIONS AND IMPLICATIONS: The finding that the voltage-dependence of inactivation and the pharmacology of Kv 1.5 + Kv β1.3 channels after PKC inhibition resembled that observed in Kv 1.5 channels suggests that both processes are dependent on PKC-mediated phosphorylation. These results may have clinical relevance in diseases that are characterized by alterations in kinase activity.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24946104      PMCID: PMC4294114          DOI: 10.1111/bph.12822

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

1.  Protein kinase A phosphorylation alters Kvbeta1.3 subunit-mediated inactivation of the Kv1.5 potassium channel.

Authors:  Y G Kwak; N Hu; J Wei; A L George; T D Grobaski; M M Tamkun; K T Murray
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

2.  Distinct domains of the voltage-gated K+ channel Kv beta 1.3 beta-subunit affect voltage-dependent gating.

Authors:  V N Uebele; S K England; D J Gallagher; D J Snyders; P B Bennett; M M Tamkun
Journal:  Am J Physiol       Date:  1998-06

3.  Open channel block of human heart hKv1.5 by the beta-subunit hKv beta 1.2.

Authors:  M De Biasi; Z Wang; E Accili; B Wible; D Fedida
Journal:  Am J Physiol       Date:  1997-06

4.  Angiotensin II and norepinephrine release: interaction and effects on the heart.

Authors:  Markus P Schlaich; David M Kaye; Elisabeth Lambert; Jacqui Hastings; Duncan J Campbell; Gavin Lambert; Murray D Esler
Journal:  J Hypertens       Date:  2005-05       Impact factor: 4.844

5.  Responses of cardiac protein kinase C isoforms to distinct pathological stimuli are differentially regulated.

Authors:  Y Takeishi; T Jalili; N A Ball; R A Walsh
Journal:  Circ Res       Date:  1999-08-06       Impact factor: 17.367

6.  Molecular determinants of stereoselective bupivacaine block of hKv1.5 channels.

Authors:  L Franqueza; M Longobardo; J Vicente; E Delpón; M M Tamkun; J Tamargo; D J Snyders; C Valenzuela
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

7.  Phosphorylation is required for alteration of kv1.5 K(+) channel function by the Kvbeta1.3 subunit.

Authors:  Y G Kwak; R A Navarro-Polanco; T Grobaski; D J Gallagher; M M Tamkun
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

Review 8.  Biologic rationale for the use of beta-blockers in the treatment of heart failure.

Authors:  Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2004-04       Impact factor: 4.214

9.  Structural determinants of potency and stereoselective block of hKv1.5 channels induced by local anesthetics.

Authors:  M Longobardo; E Delpón; R Caballero; J Tamargo; C Valenzuela
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

10.  Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension.

Authors:  J X Yuan; A M Aldinger; M Juhaszova; J Wang; J V Conte; S P Gaine; J B Orens; L J Rubin
Journal:  Circulation       Date:  1998-10-06       Impact factor: 29.690

View more
  2 in total

1.  KV1.5-KVβ1.3 Recycling Is PKC-Dependent.

Authors:  Alvaro Macias; Alicia de la Cruz; Diego A Peraza; Angela de Benito-Bueno; Teresa Gonzalez; Carmen Valenzuela
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

2.  AMP-activated protein kinase inhibits Kv 1.5 channel currents of pulmonary arterial myocytes in response to hypoxia and inhibition of mitochondrial oxidative phosphorylation.

Authors:  Javier Moral-Sanz; Amira D Mahmoud; Fiona A Ross; Jodene Eldstrom; David Fedida; D Grahame Hardie; A Mark Evans
Journal:  J Physiol       Date:  2016-06-30       Impact factor: 5.182

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.